10-KPeriod: FY2019

INTUITIVE SURGICAL INC Annual Report, Year Ended Dec 31, 2019

Filed February 7, 2020For Securities:ISRG

Summary

Intuitive Surgical, Inc. (ISRG) demonstrated strong growth in its 2019 fiscal year, with total revenue increasing by 20% to $4.5 billion, driven by a 23% increase in instrument and accessory revenue and a 19% increase in systems revenue. The company shipped 1,119 da Vinci Surgical Systems, a 21% increase year-over-year, and expanded its installed base to 5,582 systems. Procedures performed globally increased by 18% to approximately 1.23 million. The company continues to invest heavily in research and development, with a 33% increase in R&D expenses, focusing on expanding its product offerings and improving existing technologies. The introduction of new products like the Ion endoluminal system for diagnostic procedures and continued rollout of the da Vinci SP surgical system highlight the company's commitment to innovation. Despite a slight decrease in gross profit margin to 69.4% primarily due to increased amortization expenses from acquisitions, the company maintained robust profitability with operating income growing by 15% to $1.4 billion.

Financial Highlights

47 data points
Beta

Revenue

$4.48B

69.4% Gross Margin

Net Income

$1.38B

30.8% Net Margin

EPS (Diluted)

$3.85

Total Assets

$9.73B

Cash & Equivalents

$1.18B

Free Cash Flow

$1.60B

Financial Statements
Beta
Revenue$4.48B
Cost of Revenue$1.37B
Gross Profit$3.11B
R&D Expenses$557.30M
SG&A Expenses$1.18B
Operating Expenses$1.74B
Operating Income$1.37B
Net Income$1.38B
EPS (Basic)$3.98
EPS (Diluted)$3.85
Shares Outstanding (Basic)346.20M
Shares Outstanding (Diluted)358.40M

Key Highlights

  • 1Total revenue grew 20% to $4.5 billion in 2019.
  • 2Global da Vinci procedures increased by 18% to 1.23 million in 2019.
  • 3Instrument and accessory revenue, a key recurring revenue stream, grew 23% to $2.4 billion.
  • 4System shipments increased by 21% to 1,119 units, expanding the installed base to 5,582 systems.
  • 5Research and Development expenses increased by 33%, reflecting continued investment in innovation.
  • 6The company began commercial sales of its new Ion endoluminal system for diagnostic procedures.
  • 7Operating income grew 15% to $1.4 billion, demonstrating strong profitability.

Frequently Asked Questions

Intuitive Surgical's primary revenue drivers were product revenue, which increased by 22% to $3.8 billion, and service revenue, which increased by 14% to $724 million. Within product revenue, instrument and accessory sales were particularly strong, increasing by 23% to $2.4 billion, indicating robust procedure adoption and recurring revenue generation.

Intuitive Surgical is expanding its offerings into diagnostic procedures with the introduction of its Ion endoluminal system, which received FDA clearance in February 2019 for minimally invasive lung biopsies. The company also made strategic acquisitions to bolster its manufacturing capabilities, such as the acquisition of Schölly Fiberoptic's endoscope business.

Intuitive Surgical is actively investing in its international markets, with OUS revenue accounting for 30% of total revenue in 2019. The company is building out direct sales organizations in key regions like China, India, and Taiwan, aiming to increase OUS procedure volumes and revenue as a greater proportion of its overall business in the long term.

Key risks include market acceptance of robotic-assisted surgery, competition from other medical device companies, potential disruptions in manufacturing or supply chains due to sole/single-source suppliers, changes in healthcare legislation and reimbursement policies, and the inherent uncertainties of international operations, including regulatory approvals and currency fluctuations.